Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02425111 · ClinicalTrials.gov registry record · Phase 3

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

A Phase 3 study of Crohn's Disease, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
101
Enrollment target
20
Study locations

NCT02425111 is a Phase 3 study of Crohn's Disease that has completed, run by Takeda. The registered enrollment target is 101 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02425111, a Phase 3 study of Crohn's Disease, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
101 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.

Conditions Studied

Crohn's Disease

Interventions

  • DRUG Vedolizumab

Study Locations (20)

Florida

  • - Gainesville
  • - Inverness
  • - Maitland
  • - Miami
  • - Winter Park

Georgia

  • - Macon
  • - Suwanee

New York

  • - Manhasset
  • - Poughkeepsie

California

  • - La Jolla

Connecticut

  • - Hamden

Kansas

  • - Topeka

Louisiana

  • - Baton Rouge

Maryland

  • - Columbia

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2015-03-30
Est. Completion 2018-02-21
Phase Phase 3

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02425111

The ClinicalTrials.gov registry entry for NCT02425111 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (96% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Vedolizumab is the first listed.

NCT02425111 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT02425111 about?

NCT02425111 is a clinical study titled "Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease". The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.

What is the current status of trial NCT02425111?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2015-03-30. Estimated completion is 2018-02-21.

What conditions does trial NCT02425111 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT02425111?

The interventions under investigation include: Vedolizumab (DRUG).

Who is sponsoring clinical trial NCT02425111?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02425111 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Crohn's Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.